Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Gene editing shows promise as tool to fight neuro disorder in babies, UNC study findson October 23, 2020 at 12:10 pm
Babies born with a faulty maternal copy of the UBE3A gene will develop Angelman syndrome, a severe neurodevelopmental disorder with no cure and limited treatments. Now, for the first time, scientists ...
- Congress should clarify limits of gene-editing technologies, says law professoron October 21, 2020 at 11:31 pm
Genome editing of human embryos represents one of the most contentious potential scientific applications today. But what if geneticists could sidestep the controversy by editing sperm and eggs instead ...
- Congress must clarify limits of gene-editing technologieson October 21, 2020 at 10:03 am
... raised about editing embryos are applicable to editing sperm and eggs while others are not," he said. "Objections to embryonic gene editing due to the need to destroy human embryos in ...
- Paper: Congress must clarify limits of gene-editing technologieson October 21, 2020 at 7:58 am
How the next Congress decides to handle the issue editing human sperm and eggs will affect the science, ethics and financing of genomic editing for decades to come, said Jacob S. Sherkow, a professor ...
- New DNA-cutting tool could advance gene editing for novel treatmentson October 21, 2020 at 12:53 am
Gene editing for the development of new treatments, and for studying disease as well as normal function in humans and other organisms, may advance more quickly with a new tool for cutting larger ...
- Gene Editing Market 2020 to Witness Astonishing Growth with Key Players : Embrace Cibus, Recombinetics, Inc, Merck KGaA, Sangamoon October 19, 2020 at 12:04 pm
The Global Gene Editing Market report presents comprehensive information covering insightful data for businesses and investors for the time period of 2020-2027. The report studies the historical data ...
- Why the Nobel Prize shows the US and China need to work together on gene editingon October 18, 2020 at 10:00 am
They must seek new and expanded ways to identify shared principles to navigate the scientific, regulatory and ethical dimensions of this brave new world.
- EdiGene raises $67M to take gene-editing therapies into humanson October 13, 2020 at 4:30 am
EdiGene has raised around $67 million to advance work on gene-editing therapies. The Beijing-based biotech will use the series B funding to progress a pipeline led by a beta-thalassemia treatment and ...
- EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stageon October 12, 2020 at 10:00 pm
EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the successful completion of a RMB ...
- An efficient sorghum protoplast assay for transient gene expression and gene editing by CRISPR/Cas9on October 12, 2020 at 5:00 pm
Protoplasts are commonly used in genetic and breeding research. In this study, the isolation of sorghum protoplasts was optimized and applied to transient gene expression and editing by CRISPR/Cas9.
via Bing News